| 2023 | Real World Characteristics and Clinical Outcomes of HER2-Mutant Non-Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing
| CANCER RESEARCH AND TREATMENT |
| 2023 | The prognostic value of comprehensive geriatric assessment on the management of older patients with small cell lung cancer
| KOREAN JOURNAL OF INTERNAL MEDICINE |
| 2023 | Selective Inhibition of PI3K Isoforms in Brain Tumors Suppresses Tumor Growth by Increasing Radiosensitivity
| YONSEI MEDICAL JOURNAL |
| 2023 | Outcomes of an Acute Palliative Care Unit at a Comprehensive Cancer Center in Korea
| PALLIATIVE MEDICINE REPORTS |
| 2022 | Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2022 | Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study
| CLINICAL LUNG CANCER |
| 2022 | YH29407 with anti-PD-1 ameliorates anti-tumor effects via increased T cell functionality and antigen presenting machinery in the tumor microenvironment
| FRONTIERS IN CHEMISTRY |
| 2022 | Treatment outcomes and radiotherapy deintensification strategies in human papillomavirus-associated tonsil cancer
| RADIATION ONCOLOGY |
| 2022 | Role of postoperative radiotherapy in resected adenoid cystic carcinoma of the head and neck
| RADIATION ONCOLOGY |
| 2022 | Neoadjuvant Immunotherapy Following Definitive Surgical Treatment for Locoregionally Advanced Head and Neck Cancer: Perioperative Complication and Surgical Outcomes
| Korean Journal of Otorhinolaryngology-Head and Neck Surgery |
| 2022 | Continuous centrifugal microfluidics (CCM) isolates heterogeneous circulating tumor cells via full automation
| THERANOSTICS |
| 2022 | Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience | CANCER IMMUNOLOGY IMMUNOTHERAPY |
| 2022 | Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)
| LUNG CANCER |
| 2022 | Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
| 2022 | A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors
| JOURNAL OF THORACIC ONCOLOGY |
| 2022 | Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
| CLINICAL CANCER RESEARCH |
| 2022 | Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice
| CURRENT ONCOLOGY |
| 2022 | Disproportional enrichment of FoxP3(+)CD4(+) regulatory T cells shapes a suppressive tumourmicroenvironment in head and neck squamous cell carcinoma
| CLINICAL AND TRANSLATIONAL MEDICINE |
| 2022 | Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapy | RADIOTHERAPY AND ONCOLOGY |
| 2022 | The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges
| FRONTIERS IN ONCOLOGY |
| 2022 | Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma | NEW ENGLAND JOURNAL OF MEDICINE |
| 2022 | SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models
| CLINICAL & TRANSLATIONAL IMMUNOLOGY |
| 2022 | Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2022 | Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy
| IMMUNE NETWORK |
| 2022 | The importance of enhancer methylation for epigenetic regulation of tumorigenesis in squamous lung cancer
| EXPERIMENTAL AND MOLECULAR MEDICINE |
| 2022 | Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01)
| CANCER RESEARCH AND TREATMENT |
| 2022 | Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01)
| KOREAN JOURNAL OF INTERNAL MEDICINE |
| 2022 | Predicting treatment outcomes using 18 F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2021 | Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck
| ESMO OPEN |
| 2021 | Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort
| JOURNAL OF THORACIC ONCOLOGY |
| 2021 | Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
| JOURNAL OF THORACIC ONCOLOGY |
| 2021 | Therapeutic Singing as a Swallowing Intervention in Head and Neck Cancer Patients With Dysphagia
| INTEGRATIVE CANCER THERAPIES |
| 2021 | 두경부암의 최신 표적치료 | Korean Journal of Head & Neck Oncology(대한두경부종양학회지) |
| 2021 | Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma
| JOURNAL OF CLINICAL INVESTIGATION |
| 2021 | Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
| 2021 | Role and Function of O-GlcNAcylation in Cancer
| CANCERS |
| 2021 | Dysregulation of T FH-B-T RM lymphocyte cooperation is associated with unfavorable anti-PD-1 responses in EGFR-mutant lung cancer
| NATURE COMMUNICATIONS |
| 2021 | Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations
| INVESTIGATIONAL NEW DRUGS |
| 2021 | Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer
| ANNALS OF ONCOLOGY |
| 2021 | Overexpression of poliovirus receptor is associated with poor prognosis in head and neck squamous cell carcinoma patients | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY |
| 2021 | Human reference gut microbiome catalog including newly assembled genomes from under-represented Asian metagenomes | GENOME MEDICINE |
| 2021 | Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancer | EUROPEAN JOURNAL OF CANCER |
| 2021 | Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12
| CANCER RESEARCH AND TREATMENT |
| 2021 | A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
| CANCER MEDICINE |
| 2021 | Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study
| CANCERS |
| 2021 | Genetic Analysis and Operative Outcomes in Patients with Oncogene-Driven Advanced NSCLC Treated with Cytoreductive Surgery as a Component of Local Consolidative Therapy
| CANCERS |
| 2021 | Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
| CANCERS |
| 2021 | Clinical Perspectives to Overcome Acquired Resistance to Anti-Programmed Death-1 and Anti-Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer
| MOLECULES AND CELLS |
| 2021 | Clinical Insights Into Novel Immune Checkpoint Inhibitors
| FRONTIERS IN PHARMACOLOGY |
| 2021 | Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451
| JOURNAL OF CLINICAL ONCOLOGY |
http://orcid.org/0000-0002-1842-9070
(8583782700)
